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Abstract
Background: Although multiple studies have estimated the prevalence of neurological conditions in the general
Canadian population, limited research exists regarding the proportion affected with these conditions in non-acute
health care settings in Canada. Data from standardized clinical assessments based on the interRAI suite of instruments
were used to estimate the prevalence of eight neurological conditions across the continuum of care including
Alzheimer’s disease, Parkinson’s disease, epilepsy, traumatic brain injury, multiple sclerosis, cerebral palsy,
Huntington’s disease, and amyotrophic lateral sclerosis.
Methods: Cohorts of individuals receiving care in nursing homes (N = 103, 820), home care (N = 91, 021), complex
continuing care (N = 10, 581), and psychiatric hospitals (N = 23, 119) in Canada were drawn based on their most
recent interRAI assessment within each sector for a six-month period in 2010. These data were linked to the Discharge
Abstract Database and National Ambulatory Care Reporting System data sets to develop five different case definition
scenarios for estimating prevalence.
Results: The conditions with the highest estimated prevalences in these care settings in Canada were Alzheimer’s
disease and related dementias, Parkinson’s disease, epilepsy, and traumatic brain injury. However, there were notable
cross-sector differences in the prevalence of each condition, and regional variations. Prevalence estimates based on
acute hospital administrative data alone were substantially lower for all conditions evaluated.
Conclusions: The proportion of persons with neurological conditions in non-acute health care settings in Canada is
substantially higher than is generally reported for the general population. It is essential for these care settings to have
the expertise and resources to respond effectively to the strengths, preferences, and needs of the growing population
of persons with neurological conditions. The use of hospital or emergency department records alone is likely to
substantially underestimate the true prevalence of neurological conditions across the continuum of care. However,
interRAI assessment records provide a helpful source of information for obtaining these estimates in nursing home,
home care, and mental health settings.
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Background
Estimates of the prevalence of diseases are important to
various stakeholders, as they can be used to plan service
needs, allocate health care resources, prioritize research
expenditures, and raise awareness about the impact of
specific conditions. Geographic variations in prevalence
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may provide insights into risk (or protective) factors asso-
ciated with a given condition. Also, differences in the
prevalence of conditions across the continuum of health
care settings provide information about how health ser-
vices might be restructured to meet the needs of future
populations. This is particularly important for neuro-
logical conditions as many are chronic, progressive and
lifelong conditions which can as a result have a substantial
impact on health care utilization [1].
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Neurological conditions account for about 6% of the
global burden of disease, and their prevalence is expected
to continue to rise with the aging of population [2]. In
Canada, previous research has focused mainly on esti-
mating the prevalence of the most common neurological
conditions such as dementia, multiple sclerosis, epilepsy,
and Parkinson’s disease [3-8]. A paucity of estimates
exists regarding the prevalence of less common conditions
including Huntington’s disease, cerebral palsy, dystonia,
and tic disorders [9-12]. From the perspective of policy-
makers and service providers, a common limitation of
most research on neurological conditions is the tendency
to only consider prevalence in the general population
rather than within specific care settings. Further, studies
of persons in settings like nursing homes have tended to
rely on survey data, which may be affected by sampling
and non-response biases [3].
The interRAI family of assessment instruments can
provide valuable information about the prevalence of
neurological conditions and their impact on health and
well-being [13-15]. The large scale implementation of
interRAI instruments across the continuum of care in
Canada offers a new opportunity to estimate the preva-
lence of a broad range of neurological conditions in home
care, nursing home, and hospital settings [16-22]. The
present study is the first to use interRAI data holdings
linked to other health records to estimate the prevalence
of neurological conditions across the continuum of care
as part of the Innovations in Data, Evidence and Appli-
cations for Persons with Neurological Conditions project
(ideasPNC), funded by the Public Health Agency of
Canada.
The aim of this study was to examine the prevalence
of neurological conditions in home care, nursing homes,
complex continuing care, and psychiatric hospitals/
units. The neurological conditions of interest included
Alzheimer’s disease and related dementias (ADRD),
Parkinson’s disease (PD), epilepsy, traumatic brain injury
(TBI), multiple sclerosis (MS), cerebral palsy (CP), Hunt-




The data sets used for case definitions and their corre-
sponding standard data collection forms are all managed
by the Canadian Institute for Health Information (CIHI).
The clinically based data sets derived from interRAI
assessment records include the Home Care Reporting
System (HCRS) – RAI-HC, Continuing Care Reporting
System (CCRS) – RAI 2.0, and Ontario Mental Health
Reporting System (OMHRS) – RAI-MH. The adminis-
trative CIHI data sets used were the Discharge Abstract
Database (DAD) – hospital visit abstract, and theNational
Ambulatory Care Reporting System (NACRS) – emer-
gency department visit abstract.
Following data submission and quality checks, CIHI
de-identifies the individual level observations and then re-
assigns to each of them a new unique identifier, designed
to ensure that the true identity of any given person can-
not be recovered. However, this unique identifier can be
used to link all data sets mentioned above. Therefore, it is
possible to follow a person over time not only within one
sector, but throughout all care settings, including acute
and ambulatory care. The linked data sets were provided
by CIHI based on a data sharing agreement as part of the
ideasPNC project. The ideasPNC project received ethics
approval from the Office of Research Ethics, University of
Waterloo (project #17045).
HomeCare Reporting System (HCRS)
The HCRS data set contains demographic, clinical, func-
tional and resource utilization information about persons
receiving publicly funded home care programs in Canada.
The standard form used for assessment is the RAI-HC
form. RAI-HC was fully implemented in Ontario in 2006,
in Nova Scotia in 2004, and in Yukon in 2010. Persons
receiving home care are assessed at admission, discharge,
and also annually if services are received for more than a
year. Ontario clients are assessed bi-annually.
There are 864,955 records with non-missing unique
client identifier and date of assessment, collected from
362,698 persons between 2001 and 2011. The total num-
ber of persons receiving home care stabilizes around 2008
for all provinces/territories, with the exception of Nova
Scotia as agencies in this province have not submitted
RAI-HC assessments to CIHI since the first quarter of
2010 (see Additional file 1: Table S1 for more details).
The RAI-HC instruments include a record of the per-
son’s current diagnoses completed by a trained assessor
using all sources of information available including pre-
vious medical records. A “pick list” includes four neuro-
logical conditions of interest for this study (i.e., ADRD,
TBI,MS, and PD). Although there are items designated for
recording “International Classification of Diseases” ver-
sion 10, Canada (ICD-10-CA) codes [23], the de-identified
HCRS data set provided by CIHI does not include those
open-ended items. Hence, for persons receiving home
care, prevalence estimates are obtained only for diagnoses
specifically listed on the RAI-HC form, namely ADRD,
TBI, MS, and PD (see Additional file 1: Table S6 for
details).
Continuing Care Reporting System (CCRS)
The CCRS data set includes standardized measures
for residents of long-term care facilities (i.e., nursing
homes), and hospital-based continuing care facilities (i.e.,
complex care or chronic care hospitals or units). The
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CCRS contains longitudinal demographic, clinical, func-
tional, and resource utilization information about per-
sons in nursing homes and complex care hospitals, based
on the RAI 2.0 assessment. For long-term care resi-
dents, RAI 2.0 was mandated in British Columbia, Win-
nipeg Regional Heath Authority (WRHA) in Manitoba,
Ontario, and Yukon, and it was fully implemented in
these provinces/territories by 2010. In Nova Scotia, the
implementation is optional for nursing homes, and in
Newfoundland and Labrador, implementation was under-
way but not completed at the time the study data set was
constructed. For complex-continuing care clients, RAI
2.0 was fully implemented in Ontario in 1996. Also, the
instrument was implemented in one chronic-care hos-
pital in WRHA by 2010. Residents in all participating
provinces/territories are assessed at admission, quarterly
with a shorter version of RAI 2.0, and annually using the
full version of the instrument.
The CCRS data set contains 1,577,614 records with
non-missing unique identifiers and dates of assessment,
collected from 299,032 persons between 2003 and 2011.
For most provinces/territories, the number of persons
assessed every year increases over time and then stabilizes
around 2009. This can be explained by the gradual imple-
mentation of the RAI 2.0 instrument across Canada (see
Additional file 1: Table S2 for more details).
RAI 2.0 assessments contain information related to
diagnoses, either as part of a pick-list for various con-
ditions or as ICD-10-CA codes. See Additional file 1:
Tables S7–S8 for more details related to the diagnosis of
neurological conditions.
OntarioMental Health Reporting System (OMHRS)
The OMHRS data set contains information from the RAI-
MH assessments completed on individuals admitted to
inpatient mental health beds in general and specialty
facilities in Ontario. The RAI-MH instrument includes
information related to physical health, social support,
and service utilization similar to RAI 2.0 and RAI-HC,
but also includes mental-health specific information. Per-
sons receiving inpatient mental-health care are assessed
at admission, discharge, and at three-month intervals if
the length of stay is three months or greater. The instru-
ment was fully implemented in Ontario in 2006. There
are 470,586 assessments recorded in the OMHRS data
set since 2005 for 131,948 persons (see Additional file 1:
Table S3 for more details).
The RAI-MH instrument contains information regard-
ing medical diagnosis. The given pick-list does not include
any neurological condition of interest, but it does pro-
vide fields for recording ICD-10-CA codes. Also, the
psychiatric diagnostic section provides two additional
items that are relevant for identifying an ADRD case:
“delirium, dementia and amnesic and other cognitive
disorders” in the provisional psychiatric diagnostic
section, and two items in the “Psychiatric Diagnosis” –
Axis I and II – where DSM-IV codes can be recorded. The
latter items are required for completion at discharge, but
are optional in the admission assessment.
Discharge Abstract Database (DAD)
The DAD is a national database that contains demo-
graphic, administrative, and clinical data on inpatient
hospital discharges. The input document is the discharge
abstract, where relevant discharge information from the
chart is entered. Data elements that refer to related con-
cepts are grouped together, and diagnostic information
is included in the Abstracting Information Group 10 –
Diagnosis. At least one diagnosis has to be recorded
in each abstract, with the “most responsible diagnosis”
recorded as the first one for each patient. In total, up to 25
diagnoses can be recorded using the ICD-10-CA codes.
Additional file 1: Table S4 shows the number of persons
with at least one interRAI assessment in either the CCRS,
HCRS, or OMHRS data sets, who had hospital visits, by
year and by province/territory.
National Ambulatory Care Reporting System (NACRS)
The NACRS contains data on hospital-based and
community-based ambulatory care. Data collected during
a person’s visit to the emergency department (ED) include
demographic, clinical, administrative, financial, and ser-
vice information. Diagnostic information is recorded
using ICD-10-CA codes, and includes the most responsi-
ble diagnosis for the ED visit, and up to nine additional
diagnoses.
Additional file 1: Table S5 shows the number of persons
with at least one interRAI assessment in either the CCRS,
HCRS, or OMHRS data sets, who had ED visits, by year
and by province/territory.
Cohort definition
To estimate the period prevalence of the eight neurolog-
ical conditions of interest, a specific cohort for each care
setting was selected as follows.
First, a time frame (called the “index interval”) was spec-
ified to be January 1st to July 1st, 2010. This index interval
was common for all care settings. For each care setting,
all persons who had at least one assessment during the
index interval were included in the cohort. As persons
can have multiple assessments during the index interval,
the most recent assessment, called the “index” assess-
ment, was selected. The date corresponding to the index
assessment became the “index date”.
The prevalence for a neurological condition within
these specific cohorts was estimated based on the propor-
tion of cases that were identified using five different sce-
narios. These scenarios use diagnostic information from
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different sources, including the index assessment, over
different periods of time (e.g., two-year look-back window
or entire history prior to a person’s index date), and will
be described in more detail later on. Figure 1 shows the
time line for one person, where the starting point for case
definition is the index date.
Data related to the HC and MH cohorts are full-
population inventories at the provincial/territorial level,
as the implementation of RAI-HC and RAI-MH was com-
plete in the corresponding provinces at the beginning of
the index interval (i.e., January 1st to July 1st, 2010). That
is, the HC cohort includes all persons receiving long-term
home care inOntario and Yukon. TheMHcohort includes
all adults receiving inpatient psychiatric care in Ontario,
during the index interval. However, as Nova Scotia only
reported HC data for the first quarter of 2010, the corre-
sponding cohort includes all persons receiving long-term
home care during the first quarter of 2010.
Data related to the LTC cohorts from British Columbia,
Ontario, and Yukon are full-population inventories at
provincial/territorial level. ForManitoba, the data are full-
population inventories at the Winnipeg Region level. For
Nova Scotia and Newfoundland and Labrador, the cohorts
do not include all existing LTC facilities. Data related to
these cohorts are full-population inventories at the facility
level, but represent a convenience sample at the provincial
level.
The data corresponding to the CCC cohort in Ontario
are full-population inventories at provincial level. There is
also a small cohort of CCC patients from one reporting
hospital in Manitoba.
Extracting relevant diagnostic information from all sources
For each care setting, a data set containing all information
from the index assessments (i.e., information from most
recent assessment of persons in a cohort), called the index
data set, was created. Within each index data set, binary
variables corresponding towhether a person had a specific
neurological condition recorded in the index assessment
were assigned, using the diagnostic pick-list variables and
the ICD-10-CA codes as described in the Additional file 1.
Next, for each person in a cohort, information related
to diagnostic history from all interRAI sources, and from
DAD and NACRS data sets was extracted. The following
example illustrates the procedure for extracting histori-
cal diagnostic information from the DAD data set, for a
person included in the LTC cohort. The same steps were
followed for all the other sources (e.g., NACRS, HCRS),
for all persons in the LTC cohort.
First, all DAD records corresponding to this person
were selected. Then, two summary binary variables for
each neurological condition were created, using the ICD-
10-CA codes records. The first one corresponded to
whether the person had a record for a specific neuro-
logical condition in any of the available records within
the DAD data set at any time prior to the index date.
The second variable corresponded to whether the per-
son had a record for a specific neurological condition in
the DAD data set within two years prior to the index
date.
These historical variables, along with the ones extracted
from the other sources (e.g., NACRS, HCRS), were
appended to the index data set and a new “augmented”
index data set was created. Cases of a specific condition
were identified based on the information available in this
data set and using different rules for case definition as
discussed in the next section.
SAS version 9.2 (SAS Institute, Cary, NC) was used
for all data extraction and analysis. The SAS integrated
Structured Query Language (SQL) module (i.e., PROC
SQL) was used extensively for linking the data sets and
extracting the historical diagnostic information.
Scenarios for case definition
Five scenarios for case definition that are common for
all neurological conditions were defined, with the first
one being the least restrictive in terms of the number of
sources used and length of look-back window, to the last
two scenarios being themost restrictive. Table 1 shows the
information used for case definition, for each scenario.
For scenarios 1 – 4, the prevalence estimate for a neu-
rological condition in a specific care setting was obtained
Figure 1 Time frame for one person.
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Table 1 Scenarios for case definition of neurological
conditions
Scenario Sources condition Look-back
is present window
1 index assessment or index date
CCRS or HCRS or OMHRS or DAD or NACRS entire history
2 index assessment or index date
CCRS or HCRS or OMHRS or DAD or NACRS 2 years
3 index assessment or index date
DAD or NACRS 2 years
4 index assessment index date
5 DAD or NACRS 2 years
as the number of cases identified by the specific scenario
over the size of the corresponding cohort.
For scenario 5, the denominator population included
only persons who had at least one hospital or ED visit in
the last two years.
Given that the timing of implementation of interRAI
instruments differs across provinces/territories and also
that, for some provinces/territories, DAD and NACRS
records were not available (e.g., Yukon territory, see
Additional file 1: Tables S4–S5), the prevalence estimates
were calculated by province/territory and not pooled
nationally. Only prevalence estimates given by scenario
4 (i.e., based on the index interRAI assessment) can be
compared across provinces, because that scenario is the
only one unaffected by differing availability of historical
records.
For all five scenarios, point estimates are provided for
the six-month period prevalence (January 1st - July 1st,
2010) and the associated exact 95% confidence intervals
(CI), for all neurological conditions within each of the four
care settings. Also, χ2 tests for homogeneity of prevalence
given by scenario 4 across provinces/territories were con-
ducted. SAS version 9.2 (SAS Inc., Cary, NC) was used to
obtain all these results.
Using historical diagnostic invformation from the interRAI
data sets, and DAD and NACRS allows for more cases
of a certain neurological condition to be ascertained. It
is important to remember that, in the majority of cases,
the neurological conditions of interest are incurable con-
ditions; therefore, once a person is correctly diagnosed
with a condition, the diagnosis should appear in all future
records. Therefore, using historical data can help reduce
the bias of the prevalence estimator due to failure to
record the diagnosis. However, using historical diagnostic
data also poses the risk of including cases where a per-
son is wrongly diagnosed with a certain condition. It is
possible that further evaluation indicates that the person
does not have the condition, and therefore the condition
is not included in future records. In this case, defining the
client as a case based on historical records can inflate the
prevalence.
It is acknowledged that none of the scenarios presented
represents a gold standard for case definition, as errors
can occur in both historical records and most recent
ones. The main reason for combining different sources of
information is to obtain lower and upper bounds for the
prevalence estimate of a condition.
Results
For each care setting, the number of persons in the cohort
(N), the number of persons with at least one hospital or
ED visit within last 2 years (n), the mean and standard
deviation for age in years, and the percentage of females,
by province/territory, are given in Table 2.
The subset of persons selected as the cohort for the
present analyses for the HC sector included 91, 021 per-
sons. Sixty eight percent of these persons had previous
records within HCRS, 10% had a CCRS history, whereas
Table 2 Demographic characteristics of persons in cohorts,
by sector and province/territory – January 1st to July 1st,
2010
Sector & Na nb Age Sexc
province/territory Meand STD (%)
Home care
Nova Scotia 4,561 3,058 77.0 14.2 NAe
Ontario 86,378 72,927 77.7 13.4 65
Yukon 82 53 74.7 13.2 57
Long term care
British Columbia 16,307 8,405 83.8 10.3 68
Manitoba 5,714 2,534 84.7 9.5 73
Newfound. & Labrador 382 194 78.2 12.8 64
Nova Scotia 625 0 86.2 8.5 59
Ontario 80,663 54,425 83.2 10.2 70
Yukon 129 109 77.6 13.7 56
Complex cont. care
Manitoba 138 101 71.5 15.4 57
Ontario 10,443 9,578 76.4 14.1 55
Mental health care
Ontario 23,119 21,602 43.1 16.9 48
aTotal number of persons in the cohort.
bNumber of persons with at least one hospital or ED visit in last 2 years.
cPercentage of females.
dMean and standard deviation of age for all N persons in the cohort.
eGender information not available.
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72% had a DAD, and 88% a NACRS history (results not
shown, but available on request).
The subset of persons selected as the cohort corre-
sponding to the LTC sector contained 103,820 persons.
Overall, 91% of the LTC clients had a history within
the CCRS data set, 35% had a HCRS history, 4% had
an OMHRS history, 74% had a DAD history, and 73%
a NACRS history (results not shown, but available on
request).
The cohort corresponding to CCC hospitals in Ontario
included 10, 443 patients. Forty six percent of these
patients had a CCRS history, whereas 45% had a HCRS
history, 94% a DAD, and 97% a NACRS history (results
not shown, but available on request). There were also 138
patients from one chronic care hospital in Manitoba.
TheMHcohort inOntario included 23,119 persons, and
of these cases, 84% had an OMHRS history. Additionally,
44% had a DAD and 96% had a NACRS history. There are
very few in the cohort who had a CCRS or a HCRS history
(results not shown, but available on request).
Prevalence estimates among persons receiving home care
The prevalence estimates for four neurological condi-
tions (i.e., ADRD, PD, TBI, and MS) among the home
care clients from Ontario, Nova Scotia, and Yukon, and
their associated 95% exact confidence intervals are given
in Table 3. For Ontario and Yukon, the prevalence esti-
mates are six-month estimates (i.e., first six months of
2010). However, as Nova Scotia only reported HC data
for the first quarter of 2010, the corresponding prevalence
estimates are three-month period estimates.
As expected, the prevalence estimates decreased as the
case definition used fewer data sources and shorter time
spans for historical data. For example, when comparing
the prevalence estimates of ADRD based on the RAI-HC
assessment only (i.e., scenario 4) to the ones given by sce-
nario 1, the scenario 4 estimates were lower by 4% in
Ontario and by around 3% in Nova Scotia.
ADRD had the highest prevalence estimates among the
four neurological conditions. In Nova Scotia, the preva-
lence estimates ranged from 11.7% to 25%, whereas in
Ontario they ranged from 10.3% to 25.6%. In Yukon, the
ADRD prevalence estimate was 8.5% for all scenarios
except for scenario 5.
Note that the prevalence given by scenario 5 (i.e., the
scenario where only hospital and ED visits records in
the last two years were used for case definition) was the
lowest compared to the other scenarios, with estimates
ranging from 3.8% to 11.7% across provinces/territories.
Therefore, although very useful as an additional source of
diagnostic information, the hospital/ED records did not
represent a sensitive source for identifying cases when
used on their own. Based on this observation, scenario
5 is no longer considered in further discussion about
Table 3 Estimates of the prevalence of neurological
conditions by province/territory, among home care clients
assessedbetween January 1st and July 1st, 2010
Province/territory
Conditiona Nova Scotia Ontario Yukon
Scenariob (%) (CI)c (%) (CI) (%) (CI)
ADRD
1 25.0 (23.7,26.2) 25.6 (25.3,25.9) 8.5 (3.5,16.8)
2 24.2 (23.0,25.5) 24.8 (24.5,25.1) 8.5 (3.5,16.8)
3 24.1 (22.8,25.3) 24.0 (23.7,24.3) 8.5 (3.5,16.8)
4d 22.3 (21.1,23.5) 21.6 (21.3,21.9) 8.5 (3.5,16.8)
5 11.7 (10.6,12.9) 10.3 (10.0,10.5) 3.8 (0.5,13.0)
PD
1 4.3 (3.8,5.0) 5.2 (5.0,5.3) 1.2 (0.0,6.6)
2 4.1 (3.6,4.8) 5.0 (4.8,5.1) 1.2 (0.0,6.6)
3 4.1 (3.5,4.7) 4.8 (4.7,4.9) 1.2 (0.0,6.6)
4 3.7 (3.2,4.3) 4.4 (4.3,4.5) 1.2 (0.0,6.6)
5 2.5 (2.0,3.1) 2.5 (2.4,2.6) 0.0 (0.0,0.0)
TBI
1 2.5 (2.0,3.0) 3.2 (3.1,3.3) 7.3 (2.7,15.2)
2 2.1 (1.7,2.6) 2.5 (2.4,2.6) 7.3 (2.7,15.2)
3 2.0 (1.6,2.5) 2.3 (2.2,2.4) 7.3 (2.7,15.2)
4 1.6 (1.3,2.0) 1.2 (1.2,1.3) 7.3 (2.7,15.2)
5 0.9 (0.6,1.3) 1.4 (1.4,1.5) 0.0 (0.0,0.0)
MS
1 2.2 (1.8,2.7) 1.8 (1.7,1.9) 0.0 (0.0,0.0)
2 2.1 (1.7,2.6) 1.8 (1.7,1.8) 0.0 (0.0,0.0)
3 2.0 (1.6,2.5) 1.7 (1.6,1.8) 0.0 (0.0,0.0)
4 2.0 (1.6,2.4) 1.6 (1.5,1.7) 0.0 (0.0,0.0)
5 1.4 (1.0,1.9) 1.0 (0.9,1.1) 0.0 (0.0,0.0)
aADRD = Alzheimer’s Disease and Related Dementias, PD = Parkinson’s Disease,
TBI = Traumatic Brain Injury, MS = Multiple Sclerosis.
bSee Table 1 for description of each of the five case definition scenarios.
cExact 95% confidence interval.
dOnly estimates by Scenario 4 are comparable across provinces.
prevalence estimates (results are still shown in the corre-
sponding tables for information only).
The χ2 test for homogeneity suggested that the
prevalence for ADRD differed significantly across
provinces/territories (p− value = 0.009).
The prevalence estimates for PD were generally less
than 5% for Nova Scotia and Ontario, whereas in
Yukon they were 1.2% for all scenarios. The PD preva-
lence given by scenario 4 differed significantly across
provinces/territories (p− value = 0.04).
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TBI prevalence estimates ranged from 1.2% to 3.2% in
Ontario, and were up to 2.5% in Nova Scotia. In Yukon,
the prevalence estimate given by all scenarios was 7.3%.
Also, the TBI prevalence given by scenario 4 differed sig-
nificantly across provinces/territories (p−value < 0.0001)
MS had a prevalence estimate of around 2% in Nova
Scotia and Ontario. There were no reported cases of MS
among the HC clients in Yukon. There was no significant
difference between theMS prevalence given by scenario 4
across provinces/territories (p− value = 0.1).
Prevalence estimates among persons receiving
long-term care
Tables 4 – 5 show the six-month prevalence estimates
and their associated exact 95% confidence intervals for all
eight neurological conditions for long-term care residents
by province/territory.
Similar to the HC sector, ADRD was the neurological
condition with the highest prevalence, although the esti-
mates were much higher among persons in LTC homes.
Based on scenario 1, where all sources of diagnostic
information were used for case definition, the preva-
lence estimates ranged from 57.4% in Yukon to 70.3% in
Manitoba.
The prevalence estimates given by scenario 4, where
only the RAI 2.0 index assessment was used for case
definition, ranged from 41.9% in Yukon to 62.6% in
Manitoba. The χ2 test for homogeneity suggested that
the prevalence of ADRD differed significantly across
provinces/territories (p− value < 0.0001).
The neurological condition with the second highest
prevalence estimate among the LTC residents was PD.
In Ontario, the prevalence ranged from 6.9% to 8.4%
(excluding scenario 5). We see similar values in British
Columbia and Manitoba. In Newfoundland and Labrador,
Nova Scotia, and Yukon, the prevalence was less than 4%.
The prevalence given by scenario 4 differed significantly
across provinces/territories (p− value < 0.0001).
The epilepsy prevalence estimate was as high as 7.8% in
Yukon and 7.3% in Newfoundland and Labrador, as given
by scenario 1. In Ontario, the prevalence ranged from
5.2% to 6.3%. The prevalence given by scenario 4 differed
significantly across provinces/territories (p − value <
0.0001).
The remaining neurological conditions had substan-
tially lower prevalence estimates. TBI had a prevalence
estimate ranging from 1% to 4% in Ontario, and from 0.3%
to 0.6% in Nova Scotia.
MS had a prevalence estimate of less than 2% for all
provinces, except for Yukon, where the estimate was 3.9%
for all scenarios.
The prevalence estimate of CP was lower than 1% for
all provinces/territories, except for Newfoundland and
Labrador, where the estimates ranged from 1.8% to 2.6%.
The prevalence estimate of HD was less than 1% for all
provinces/territories, whereas the prevalence for ALS was
less than 0.5%.
Prevalence estimates among persons receiving
complex-continuing care
Table 6 shows the six-month prevalence estimates for all
neurological conditions, for persons in CCC hospitals/
units in Ontario and Manitoba.
Again, ADRD was the condition with the highest preva-
lence estimates, although the estimates were not as high
as in the LTC sector. In Ontario, the prevalence of ADRD
ranged from 26.6% to 33.6%, whereas in Manitoba it
ranged from 15.9% to 21.7%.
In Ontario, the prevalence estimates for epilepsy ranged
from 6.1% to 8% and were higher than in the LTC sector.
For PD, the prevalence estimates were about 2% lower in
CCC than in LTC inOntario, with estimated ranging from
5% to 6.4%.
Also, slightly higher prevalence estimates were seen in
the CCC sector in Ontario for TBI, MS, and ALS, when
compared to the ones among LTC residents.
Prevalence estimates among persons receiving
mental-health care – Ontario
Table 7 shows the six-month prevalence estimates for
seven neurological conditions, for the Ontario MH
cohort. The prevalence estimate for ALS ranged from
0.02% to 0.03%.
Among the persons in inpatient psychiatry, the ADRD
prevalence estimates ranged from 6.3% to 10%. Epilepsy
and TBI had prevalence estimates up to 3%, whereas the
PD prevalence estimates were less than 2%.
CP, HD, and MS had prevalence estimates lower than
0.5%.
Discussion
This study provided new information regarding the preva-
lence of eight neurological conditions within four clinical
settings in the continuum of care that had received lit-
tle attention in the literature. For each condition, cases
were identified using data from the interRAI assessments
and other databases such as acute and ambulatory care,
using data linkage. The study provided lower and upper
bounds for the estimates of a six-month period preva-
lence using five different case definitions. These sce-
narios used different combinations of diagnostic sources
and different lengths of look-back windows for histor-
ical data. This was the first Canadian or international
study to our knowledge to provide prevalence estimates
within all four care settings. In most sectors, the study
results were based on full-population data at the provin-
cial/territorial level from January through June 2010,
except for Newfoundland and Labrador and Nova Scotia
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Table 4 Estimates of prevalence of neurological conditions by province/territory, among LTC home residents assessed
between January 1st and July 1st, 2010
Province/Territory
Conditiona British Manitoba Newfound. & Nova Scotia Ontario Yukon
& Columbia Labrador
Scenariob (%) (CI)c (%) (CI) (%) (CI) (%) (CI) (%) (CI) (%) (CI)
ADRD
1 69.7 (69.0,70.4) 70.3 (69.1,71.5) 68.6 (63.7,73.2) 65.0 (61.1,68.7) 66.0 (65.7,66.4) 57.4 (48.4,66.0)
2 67.8 (67.1,68.6) 68.2 (67.0,69.4) 67.8 (62.9,72.5) 64.0 (60.1,67.8) 64.3 (64.0,64.6) 53.5 (44.5,62.3)
3 62.5 (61.7,63.2) 65.9 (64.6,67.1) 59.2 (54.0,64.1) 60.3 (56.4,64.2) 60.6 (60.2,60.9) 47.3 (38.4,56.3)
4d 58.9 (58.2,59.7) 62.6 (61.4,63.9) 56.3 (51.1,61.3) 60.3 (56.4,64.2) 57.9 (57.6,58.2) 41.9 (33.2,50.9)
5 34.8 (33.8,35.8) 43.9 (41.9,45.8) 28.9 (22.6,35.8) NAe 27.1 (26.8,27.5) 22.0 (14.6,31.0)
PD
1 6.7 (6.4,7.1) 7.2 (6.5,7.9) 4.2 (2.4,6.7) 4.0 (2.6,5.8) 8.4 (8.2,8.6) 3.9 (1.3,8.8)
2 6.2 (5.8,6.6) 6.7 (6.0,7.3) 3.4 (1.8,5.7) 4.0 (2.6,5.8) 7.8 (7.6,8.0) 3.9 (1.3,8.8)
3 6.0 (5.6,6.4) 6.4 (5.8,7.1) 3.4 (1.8,5.7) 3.4 (2.1,5.1) 7.3 (7.2,7.5) 3.9 (1.3,8.8)
4 5.6 (5.2,5.9) 5.9 (5.3,6.5) 2.1 (0.9,4.1) 3.4 (2.1,5.1) 6.9 (6.8,7.1) 3.1 (0.9,7.7)
5 4.0 (3.6,4.4) 4.9 (4.1,5.8) 3.1 (1.1,6.6) NA 3.6 (3.5,3.8) 2.8 (0.6,7.8)
Epilepsy
1 4.0 (3.7,4.3) 4.7 (4.2,5.3) 7.3 (4.9,10.4) 3.2 (2.0,4.9) 6.3 (6.2,6.5) 7.8 (3.8,13.8)
2 3.7 (3.4,4.0) 4.7 (4.1,5.2) 6.8 (4.5,9.8) 3.0 (1.8,4.7) 6.0 (5.8,6.2) 6.2 (2.7,11.9)
3 3.5 (3.2,3.7) 4.4 (3.9,5.0) 6.8 (4.5,9.8) 2.7 (1.6,4.3) 5.5 (5.4,5.7) 6.2 (2.7,11.9)
4 3.2 (2.9,3.4) 4.2 (3.7,4.8) 6.5 (4.3,9.5) 2.7 (1.6,4.3) 5.2 (5.1,5.4) 5.4 (2.2,10.9)
5 1.6 (1.3,1.9) 1.0 (0.7,1.5) 2.6 (0.8,5.9) NA 1.5 (1.4,1.6) 2.8 (0.6,7.8)
TBI
1 3.4 (3.1,3.7) 1.6 (1.3,2.0) 2.4 (1.1,4.4) 0.6 (0.2,1.6) 4.0 (3.9,4.2) 3.9 (1.3,8.8)
2 2.5 (2.3,2.8) 1.1 (0.8,1.4) 1.8 (0.7,3.7) 0.5 (0.1,1.4) 2.5 (2.4,2.6) 3.9 (1.3,8.8)
3 2.4 (2.2,2.6) 1.0 (0.8,1.3) 1.6 (0.6,3.4) 0.3 (0.0,1.2) 1.9 (1.8,2.0) 3.1 (0.9,7.7)
4 1.4 (1.3,1.6) 0.6 (0.5,0.9) 1.6 (0.6,3.4) 0.3 (0.0,1.2) 0.9 (0.8,1.0) 1.6 (0.2,5.5)
5 2.2 (1.9,2.5) 1.0 (0.7,1.5) 1.5 (0.3,4.5) NA 1.7 (1.6,1.8) 1.8 (0.2,6.5)
aADRD = Alzheimer’s Disease and Related Dementias, PD = Parkinson’s Disease, TBI = Traumatic Brain Injury.
bSee Table 1 for description of each of the five case definition scenarios.
cExact 95% confidence interval.
dOnly estimates by Scenario 4 are comparable across provinces/territories.
eNo hospital or ED visits for LTC clients in this province.
for the LTC sector, and Manitoba for the CCC sec-
tor. Results for persons in LTC facilities from Manitoba
were based on full-population data at a regional level
(WRHA).
The neurological condition with the highest prevalence
estimate in all four care settings was ADRD, which proba-
bly reflects the advanced age and functional impairments
typical of persons in these settings. In the HC sector,
the upper bound of the ADRD prevalence estimate was
around 25% in Nova Scotia and Ontario, and around
9% in Yukon. The upper bound of the estimate ranged
from 57% to 70% among persons receiving LTC in six
provinces/territories, and was as high as 34% among CCC
patients in Ontario. The LTC results are comparable to
previous studies [4,24,25]. Also, 10% of inpatient mental-
health patients in Ontario were identified as ADRD cases
when all sources of diagnostic information are considered.
The prevalence of ADRD and other neurological con-
ditions in home care and long-term care varied across
regions. For example, persons receiving care in the Yukon
often had notably different estimated prevalence com-
pared with other regions. Future research is needed to
understand whether these regional variations reflect dif-
ferences in policy or practice across provinces or differ-
ences in the characteristics of the underlying populations.
The prevalence estimate of PD was as high as 8% in
the LTC sector, which is reasonably comparable to the
estimate provided by a previous Canadian study (Moghal
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Table 5 Estimates of the prevalence of neurological conditions by province/territory, among LTC home residents
assessedbetween January 1st and July 1st, 2010
Province/Territory
Conditiona British Manitoba Newfound. & Nova Scotia Ontario Yukon
& Columbia Labrador
Scenariob (%) (CI)c (%) (CI) (%) (CI) (%) (CI) (%) (CI) (%) (CI)
MS
1 1.6 (1.4,1.8) 1.5 (1.2,1.9) 1.0 (0.3,2.7) 0.2 (0.0,0.9) 1.4 (1.4,1.5) 3.9 (1.3,8.8)
2 1.5 (1.3,1.7) 1.5 (1.2,1.9) 1.0 (0.3,2.7) 0.2 (0.0,0.9) 1.4 (1.3,1.5) 3.9 (1.3,8.8)
3 1.4 (1.2,1.6) 1.5 (1.2,1.8) 1.0 (0.3,2.7) 0.2 (0.0,0.9) 1.3 (1.3,1.4) 3.9 (1.3,8.8)
4d 1.4 (1.2,1.6) 1.5 (1.2,1.8) 0.8 (0.2,2.3) 0.2 (0.0,0.9) 1.3 (1.2,1.4) 3.9 (1.3,8.8)
5 0.8 (0.6,1.0) 1.5 (1.0,2.0) 1.0 (0.1,3.7) NAe 0.9 (0.8,0.9) 1.8 (0.2,6.5)
CP
1 0.5 (0.4,0.6) 0.4 (0.3,0.6) 2.6 (1.3,4.8) 0.5 (0.1,1.4) 0.7 (0.6,0.7) 0.8 (0.0,4.2)
2 0.5 (0.4,0.6) 0.4 (0.3,0.6) 2.6 (1.3,4.8) 0.5 (0.1,1.4) 0.6 (0.6,0.7) 0.8 (0.0,4.2)
3 0.4 (0.3,0.5) 0.4 (0.2,0.5) 2.1 (0.9,4.1) 0.5 (0.1,1.4) 0.5 (0.5,0.6) 0.8 (0.0,4.2)
4 0.4 (0.3,0.5) 0.3 (0.2,0.5) 1.8 (0.7,3.7) 0.5 (0.1,1.4) 0.5 (0.5,0.6) 0.8 (0.0,4.2)
5 0.2 (0.2,0.4) 0.1 (0.0,0.3) 1.0 (0.1,3.7) NA 0.2 (0.2,0.3) 0.0 (0.0,0.0)
HD
1 0.3 (0.2,0.4) 0.3 (0.2,0.5) 0.5 (0.1,1.9) 0.2 (0.0,0.9) 0.3 (0.3,0.3) 0.8 (0.0,4.2)
2 0.3 (0.2,0.4) 0.3 (0.2,0.5) 0.5 (0.1,1.9) 0.2 (0.0,0.9) 0.3 (0.3,0.3) 0.8 (0.0,4.2)
3 0.3 (0.2,0.4) 0.3 (0.2,0.5) 0.5 (0.1,1.9) 0.2 (0.0,0.9) 0.3 (0.2,0.3) 0.8 (0.0,4.2)
4 0.3 (0.2,0.4) 0.3 (0.2,0.5) 0.5 (0.1,1.9) 0.2 (0.0,0.9) 0.3 (0.2,0.3) 0.0 (0.0,0.0)
5 0.2 (0.1,0.3) 0.2 (0.1,0.5) 0.5 (0.0,2.8) NA 0.1 (0.1,0.2) 0.9 (0.0,5.0)
ALS
1 0.5 (0.4,0.6) 0.1 (0.1,0.3) 0.3 (0.0,1.4) 0.3 (0.0,1.2) 0.3 (0.3,0.4) 0.0 (0.0,0.0)
2 0.4 (0.3,0.6) 0.1 (0.0,0.3) 0.3 (0.0,1.4) 0.3 (0.0,1.2) 0.3 (0.3,0.3) 0.0 (0.0,0.0)
3 0.4 (0.3,0.5) 0.1 (0.0,0.2) 0.0 (0.0,0.0) 0.2 (0.0,0.9) 0.2 (0.2,0.3) 0.0 (0.0,0.0)
4 0.3 (0.2,0.4) 0.1 (0.0,0.2) 0.0 (0.0,0.0) 0.2 (0.0,0.9) 0.2 (0.1,0.2) 0.0 (0.0,0.0)
5 0.3 (0.2,0.5) 0.1 (0.0,0.3) 0.0 (0.0,0.0) NA 0.2 (0.1,0.2) 0.0 (0.0,0.0)
aMS =Multiple Sclerosis, CP = Cerebral Palsy, HD = Huntington’s Disease, ALS = Amyotrophic Lateral Sclerosis.
bSee Table 1 for description of each of the five case definition scenarios.
cExact 95% confidence interval.
dOnly estimates by Scenario 4 are comparable across provinces/territories.
eNo hospital or ED visits for LTC clients in this province.
et al. [8] reported a prevalence estimate of 6% among
nursing home residents). The PD prevalence was around
5% among persons receiving HC in Nova Scotia and
Ontario, and was around 6% amongOntario complex con-
tinuing care hospital patients. The upper bound of the
PD prevalence estimate was around 2% in the Ontario
psychiatric hospital sector.
The prevalence estimate for epilepsy was as high as 8%
in the LTC and CCC sectors, and was around 3% among
mental health patients in Ontario. These estimates are
higher than those seen in the general population (e.g.,
Tellez-Zenteno et al. [5] estimated the prevalence to be
around 0.5− 0.6%). However, this is not unexpected con-
sidering that the prevalence of epilepsy increases with age
and the individuals studied here were expected to be less
healthy than the general population, with more comor-
bid conditions that can be associated with epilepsy (e.g.,
stroke, neurodegenerative conditions).
Among persons receiving LTC in Ontario and Yukon,
4% were identified as TBI cases when all diagnostic
sources were used. In the home-care sector in Ontario
and Nova Scotia, and in the mental-health care sector
in Ontario, the prevalence estimate for TBI was around
3%, whereas in the CCC sector in Ontario it was 6%.
Prevalence studies of TBI are extremely rare, asmost stud-
ies focus on the incidence of TBI. One Canadian study
reported an age-standardized prevalence of TBI of 50.4
per 100, 000 in 2001-2002 [26].
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Table 6 Estimates of the prevalence of neurological conditions by province/territory, among Complex Continuing Care
(CCC) hospital patients assessedbetween January 1st and July 1st, 2010
Province & Conditiona
Scenariob ADRD PD EPILEPSY TBI MS CP HD ALS
Ontario
1 33.6c (32.7,34.5)d 6.4 (5.9,6.9) 8.0 (7.5,8.5) 5.6 (5.2,6.1) 2.4 (2.2,2.8) 1.1 (0.9,1.3) 0.4 (0.3,0.5) 1.1 (0.9,1.3)
2 32.6 (31.7,33.6) 6.1 (5.6,6.6) 7.3 (6.8,7.8) 4.6 (4.2,5.0) 2.3 (2.0,2.6) 0.9 (0.7,1.1) 0.3 (0.2,0.5) 0.9 (0.7,1.1)
3 29.7 (28.9,30.6) 5.7 (5.3,6.1) 6.7 (6.3,7.2) 4.0 (3.6,4.4) 2.2 (1.9,2.5) 0.8 (0.6,1.0) 0.3 (0.2,0.5) 0.8 (0.6,1.0)
4 26.6 (25.8,27.5) 5.0 (4.6,5.5) 6.1 (5.7,6.6) 2.5 (2.2,2.8) 2.1 (1.8,2.4) 0.7 (0.5,0.9) 0.3 (0.2,0.4) 0.6 (0.5,0.8)
5 15.9 (15.2,16.7) 4.0 (3.6,4.4) 2.3 (2.0,2.6) 2.4 (2.1,2.8) 1.4 (1.2,1.7) 0.5 (0.3,0.6) 0.2 (0.1,0.3) 0.5 (0.4,0.7)
Manitoba
1 21.7 (15.2,29.6) 5.8 (2.5,11.1) 9.4 (5.1,15.6) 11.6 (6.8,18.1) 5.8 (2.5,11.1) 0.7 (0.0,4.0) 0.7 (0.0,4.0) 1.4 (0.2,5.1)
2 20.3 (13.9,28.0) 5.1 (2.1,10.2) 8.0 (4.0,13.8) 11.6 (6.8,18.1) 5.8 (2.5,11.1) 0.7 (0.0,4.0) 0.7 (0.0,4.0) 0.7 (0.0,4.0)
3 18.8 (12.7,26.4) 5.1 (2.1,10.2) 7.2 (3.5,12.9) 11.6 (6.8,18.1) 4.3 (1.6,9.2) 0.7 (0.0,4.0) 0.7 (0.0,4.0) 0.7 (0.0,4.0)
4 15.9 (10.3,23.1) 5.1 (2.1,10.2) 7.2 (3.5,12.9) 6.5 (3.0,12.0) 4.3 (1.6,9.2) 0.7 (0.0,4.0) 0.7 (0.0,4.0) 0.7 (0.0,4.0)
5 15.8 (9.3,24.4) 3.0 (0.6,8.4) 0.0 (0.0,0.0) 7.9 (3.5,15.0) 3.0 (0.6,8.4) 1.0 (0.0,5.4) 0.0 (0.0,0.0) 1.0 (0.0,5.4)
aADRD = Alzheimer’s Disease and Related Dementias, PD = Parkinson’s Disease, TBI = Traumatic Brain Injury, MS = Multiple Sclerosis, CP = Cerebral Palsy,
HD = Huntington’s Disease, ALS = Amyotrophic Lateral Sclerosis.
bSee Table 1 for description of each of the five case definition scenarios.
cPrevalence estimate expressed as a percentage (%).
dExact 95% CI.
The upper bound for the prevalence estimate of MS
was less than 2% among LTC clients in all five provinces,
and among HC clients in Ontario and Nova Scotia, and it
was 4% among LTC clients in Yukon. Similarly to epilepsy,
these estimates were higher than those reported in the
general Canadian population [6], ranging from 56 to 298
per 100,000, possibly reflecting the complex physical, cog-
nitive, and psychosocial demands of this progressively
disabling disease. Among people over 65 years with MS
living in Canada, Finlayson [27] found nursing home esti-
mates of 5.8% (of 274) and 9.2% (of 142), similar to those
reported in the United States [28,29].
For ALS, CP, and HD, the prevalence estimates were
lower than 1% in the LTC and HC sectors, except for the
prevalence of CP in LTC in Newfoundland and Labrador,
where the estimate was 3%. In Ontario, the prevalence
estimates for these conditions were slightly higher in the
CCC sector than in the LTC sector. However, the preva-
lence of ALS and HD were about 100 fold higher in
these settings than what has been reported in the gen-
eral population, at 4.9 and 2.71 per 100, 000 respectively
[12,30]. This is not surprising as patients with ALS and
HD would be expected to be primarily cared for in these
settings, due to the significant functional deficits they
experience [31,32].
Previous research has provided evidence of the validity
of diagnostic information in these various interRAI data-
bases [33]. The interRAI assessment approach requires
Table 7 Estimates of the prevalence of neurological conditions among Ontario PsychiatricHospital Inpatients assessed
between January 1st and July 1st, 2010
Conditiona
Scenariob ADRD PD Epilepsy TBI MS CP HD
1 10.0c (9.6,10.4)d 1.7 (1.5,1.8) 3.0 (2.7,3.2) 2.6 (2.4,2.8) 0.3 (0.3,0.4) 0.3 (0.3,0.4) 0.3 (0.2,0.3)
2 9.0 (8.7,9.4) 1.3 (1.1,1.4) 2.4 (2.2,2.6) 1.8 (1.6,2.0) 0.3 (0.2,0.4) 0.3 (0.3,0.4) 0.3 (0.2,0.3)
3 6.9 (6.6,7.3) 1.0 (0.9,1.2) 1.9 (1.8,2.1) 1.5 (1.3,1.6) 0.3 (0.2,0.3) 0.3 (0.2,0.3) 0.2 (0.2,0.3)
4 6.3 (6.0,6.6) 0.5 (0.4,0.6) 0.6 (0.5,0.7) 0.1 (0.1,0.2) 0.1 (0.1,0.2) 0.2 (0.1,0.2) 0.2 (0.1,0.3)
5 3.3 (3.0,3.5) 0.8 (0.7,0.9) 1.6 (1.5,1.8) 1.5 (1.3,1.6) 0.2 (0.2,0.3) 0.2 (0.1,0.3) 0.2 (0.1,0.2)
aADRD = Alzheimer’s Disease and Related Dementias, PD = Parkinson’s Disease, TBI = Traumatic Brain Injury, MS = Multiple Sclerosis, CP = Cerebral Palsy, HD =
Huntington’s Disease.
bSee Table 1 for description of each of the five case definition scenarios.
cPrevalence estimate expressed as a percentage (%).
dExact 95% CI.
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the use of all sources of information as evidence to be
considered by assessors, including medical records, inter-
views, and observations of the person being assessed, and
consultation with family members and other health pro-
fessionals. Although this approach is the standard across
all provinces/territories using the instruments in Canada,
it may be the case that variations in access to special-
ized diagnostic services may account for some of the
regional variations in prevalence estimates. For example,
differences in the availability of advanced medical test-
ing (e.g., access to genetic testing or clinical evaluation
by neurologists or geriatricians) may affect the ascertain-
ment of cases from themedical record thereby influencing
prevalence estimates.
It might be the case that eligibility criteria could affect
the prevalence estimates within specific sectors, but it
is unlikely that this is an explanation for the differences
between the Canadian provinces/territories reported
here. Studies comparing the nursing home [19] and home
care [34] populations across Canada showed only mod-
est differences in the case mix distributions and need
profiles of persons in these care settings in different
provinces/territories.
The results demonstrated that neurological conditions
are an important source of morbidity in complex contin-
uing care hospital, nursing home, and home care settings.
These prevalence estimates were considerably higher than
estimates based on the general population as a whole [5,6].
The high prevalence estimates, particularly for conditions
like dementia and Parkinson’s Disease, suggest that atten-
tionmust be paid to ensure that staff in those settings have
appropriate training and expertise to deal with the needs
of persons with these conditions. The extent to which the
policies and practices in different care settings support
the needs of people with neurological conditions requires
urgent examination.
Although the neurological conditions considered here
are much less common in inpatient psychiatry, they were
present, and highlighted the well-recognized burden of
psychiatric comorbidity in neurologic diseases [35-37].
Persons with comorbid neurological conditions in psychi-
atry may have special needs not evident in the general
population served by mental health care providers. Mul-
tiple sclerosis is associated with a very high prevalence
of mood disorders in the general population [36], yet the
prevalence estimates of MS in the mental health settings
were only slightly higher than that of the general popu-
lation. A possible explanation is that psychiatric hospital
settings may not be viewed as a suitable care setting for
people with MS due to their medical needs.
From a methodological perspective, the range of preva-
lence estimates was not greatly affected by the case def-
inition assumptions made in the different case definition
scenarios. The only clear outliers in prevalence estimates
came from the exclusive use of DAD and NACRS records
which almost certainly yield substantial under-estimates
of the true prevalence of these conditions. Although
all available records in the DAD and NACRS diagno-
sis section were used for case definition of neurological
conditions (i.e., “most responsible diagnosis” and other
diagnoses), there may have been cases where the neu-
rological conditions of interest were not recorded at all
because theywere not themain reason for being admitted.
It is well known that comorbid diagnoses are less likely
to be included in the hospital or ER discharge records
[38,39]. Therefore, it is not surprising that some cases are
missed when the case definition is based on the DAD and
NACRS records only, which results in under-estimation of
the prevalence.
Therefore, the interRAI instruments are more useful
for obtaining prevalence estimates across the continuum
of care than acute hospital-based administrative records.
However, as clinical assessment instruments the interRAI
instruments also have great value because they provide a
broad range of clinical indicators that can be used to fur-
ther examine the clinical characteristics of persons with
neurological conditions. Future efforts to refine HCRS,
CCRS, and OMHRS should explore options to further
enhance the diagnostic items in the interRAI assessments
to conveniently (and reliably) capture diagnostic data not
currently on the standard pick list.
The focus of this study was to explore different method-
ologies for comparing the period prevalence over a certain
time interval (i.e., January through June, 2010). In the
future, it would interesting to investigate how the preva-
lence in the four sectors of interest changes over time,
and to compare the trends for the prevalence as defined
by different scenarios and across provinces. In addition,
the present study focused on prevalence estimates within
a sector in a given time period; however, individuals
were not constrained to appearing in only a single sec-
tor. Therefore, it may be the case that persons who were
admitted from home care to nursing homes would con-
tribute to the period prevalence estimates of both care
settings by virtue of having received services and assess-
ments in both settings. This may be problematic if one
were estimating prevalences in the total population based
on these data, but it is not a concern when estimating
prevalences within individual sectors.
Limitations
This study had several limitations. First, due to gradual
implementation of the interRAI instruments, some
provinces had more historical interRAI data than others,
which makes the provincial prevalence estimates given by
some scenarios not comparable. This issue will become
less important over time as these provinces continue
to widely implement these instruments. Second, not all
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provinces/territories reported acute or ambulatory care
abstracts (e.g., Yukon). Therefore, comparisons between
provinces are not recommended when the case defi-
nition involves historical data from the DAD and/or
NACRS. Also, some Canadian provinces/territories have
just recently started implementing interRAI instruments
(e.g., Alberta), whereas others have not implemented any
of them (e.g., Quebec). Therefore, national-level preva-
lence estimates for neurological conditions within all four
care settings are not possible at this time. An alternative
to the approach taken here, where partial data were used
for some provinces/territories, would have been to con-
sider only provinces/territories with complete interRAI
data (e.g., Ontario for the LTC and HC sectors). However,
this approach would have drastically limited the analysis
and would have omitted useful information.
The RAI-HC diagnoses pick list includes only four neu-
rological conditions (i.e., ADRD, PD, MS, and TBI) and
the ICD-10-CA codeswere not available for the other con-
ditions. Therefore, for the HC sector, prevalence estimates
could not be provided for some of the common neurolog-
ical conditions such as epilepsy. In addition, the older ver-
sions of interRAI instruments employed here have some
variability in diagnostic terminology (e.g., some refer to
parkinsonism and other Parkinson’s disease); however,
these variations have been eliminated in newer versions
of these instruments to adhere to a single cross-sector
standard [13].
In the RAI-MH instrument, dementia can be captured
in three ways: by recording the corresponding ICD-10-
CA codes, by checking the item “delirium, dementia and
amnesic and other cognitive disorders” in the provisional
diagnostic section, or by entering the DSM-IV codes, in
the psychiatric diagnosis section. However, in some cases
the provisional diagnosis item “delirium, dementia and
amnesic and other cognitive disorders” may be checked
off to identify a diagnosis other than dementia, which
might inflate the prevalence estimate of dementia.
As part of the on-going research related to the devel-
opment of interRAI instrument, studies of the valid-
ity of the diagnostic codes on these assessments have
been done in the nursing home and CCC sectors com-
pared with acute hospital records [40,41]. Forthcoming
research arising from the ideasPNC project extends this
research to include the HC and MH sectors (results
available on request). Clinicians completing interRAI
assessments are trained to use all sources of informa-
tion available including direct observation of the per-
son, interviews with other informants, consultations with
other colleagues, medical records, and the chart. They
then use their clinical judgement to record observations on
all interRAI items, including diagnostic codes. Nonethe-
less, the potential for misdiagnosis, under-ascertainment
or over-ascertainment of certain conditions remains. It
would be helpful for further research to be undertaken
comparing the interRAI assessment data against system-
atic, expert reviews of longitudinal medical records or
direct patient assessment by neurologists to more fully
evaluate the validity of those items. Further, ICD coding,
and in particular ICD-10 coding has not been validated for
most neurological conditions. Some codes are highly spe-
cific such as MS which has a single code, while others are
nonspecific [42].
Two other data sources have been used in previous stud-
ies for case identification [43]. These include physician
services/billing and prescription medication data. These
additional sources of informationmight help identify even
more cases of persons with neurological conditions across
the continuum of care, and should be considered in future
prevalence studies.
Conclusion
Compared with previous reports on the prevalence of
neurological conditions in the general population, there
is a substantially higher proportion of Canadians in non-
acute health care settings affected by these conditions.
This was true for the most common conditions like
Alzheimer’s and related dementias, but it also applied to
less prevalent neurological conditions. As a result, it is
particularly important for staff to have the expertise and
resources to respond effectively to the strengths, pref-
erences, and needs of this population. While hospital
and emergency department records provided useful sup-
plementary information for estimating the prevalence of
various neurological conditions, they would substantially
underestimate the true prevalence of these conditions if
used on their own. However, interRAI assessment records
provide a helpful source of information for obtaining
these estimates in nursing home, home care, and mental
health settings. These assessments can provide evidence
about the prevalence of neurological conditions as well as
important multidimensional evidence on the clinical char-
acteristics and service utilization patterns of this growing
population.
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